We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


ACON Laboratories provides rapid diagnostic and healthcare products and the company’s in vitro diagnostic product lin... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Point-of-Care Testing Device Evaluated for Anemia Detection

By LabMedica International staff writers
Posted on 14 Sep 2021
Print article
Image: The Mission Ultra Hb Testing System portable point-of-care testing device detects anemia (Photo courtesy of ACON Laboratories)
Image: The Mission Ultra Hb Testing System portable point-of-care testing device detects anemia (Photo courtesy of ACON Laboratories)
Anemia is a serious public health problem worldwide. Several methods are commonly used to assess an individuals’ hemoglobin (Hb) and hematocrit (Hct) levels, including automated hematology analyzers, microhematocrit centrifuge, gravimetric copper sulfate method, cyanmethemoglobin method, and color code Hb estimation.

Although automated hematology analyzers are the gold standard and produce significantly accurate results for diagnosing anemia, their availability is limited to the regional, provincial, and district hospital levels. In resource-poor settings, a handheld or portable point-of-care testing (POCT) device for Hb and Hct level assessment potentially plays a key role as a tool for anemia detection, improving the problems of delayed diagnosis and interventions that lead to increased morbidity and mortality.

Clinical Laboratorians at the Phramongkutklao College of Medicine (Bangkok, Thailand) conducted a prospective and hospital-based study to compare a new POCT Hb Testing System with an automated hematology analyzer in Thai adult males and non-pregnant adult females. A total of 300 participants were involved in the study and were aged between 20 and 94 years, with 50.7% of them being anemic.

The team used the POCT device the Mission Ultra Hb Testing System (ACON Laboratories, Inc., San Diego, CA, USA) that consists of a handheld meter and disposable test strips. The device uses the principle of electrochemistry for Hb detection, while Hct is measured by electrical impedance. The POCT device was compared with the Sysmex XN-3000 hematology analyzer (Sysmex Corp., Kobe, Japan) which is an automated blood cell counter for diagnostic use in clinical laboratories. Sysmex XN-3000 uses cyanide-free sodium lauryl sulfate (SLS) to determine Hb levels, whereas Hct level is measured based on the principle of hydrodynamic focusing.

The investigators reported that in all participants, near-perfect correlation and agreement were observed between the two methods for Hb measurement (r = 0.963) with an interclass correlation coefficient (ICC) of 0.981 and Hct measurement (r = 0.941) with an ICC of 0.965. The sensitivity and specificity of the device in detecting anemia were 86.2% and 98.6% , respectively. The area under the curve was 0.976. The device showed average biases of 0.76 g/dL (95% limits of agreement [LOA]: −1.03 to 2.54) for Hb measurement and −2.73% (95% LOA: −9.28 to 3.82) for Hct measurement in all participants.

The authors concluded that venous Hb and Hct determinations using the Mission Ultra Hb Testing System were in acceptable agreement with the measurements obtained from the automated hematology analyzer. The performance of the device for detecting anemia was excellent. However, the essential evidence showing biases of the Hb and Hct measurements obtained from the device was revealed; therefore, laboratory interpretation should be carefully performed, particularly at the near cut-off values. The study was published on August 24, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Phramongkutklao College of Medicine
ACON Laboratories
Sysmex Corp

Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
Gold Supplier
SARS-CoV-2 S-IgG Antibody Assay
Lumipulse G SARS-CoV-2 S-IgG
Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
Silver Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.